Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

PHASE3CompletedINTERVENTIONAL
Enrollment

537

Participants

Timeline

Start Date

November 24, 2015

Primary Completion Date

April 3, 2019

Study Completion Date

April 3, 2019

Conditions
Bacterial Pneumonia
Interventions
DRUG

Imipenem

Imipenem 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days

DRUG

Relebactam

Relebactam 250 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days

DRUG

Cilastatin

Cilastatin 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days

DRUG

Piperacillin

Piperacillin 4000 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days

DRUG

Tazobactam

Tazobactam 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days

DRUG

Linezolid

Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02493764 - Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) | Biotech Hunter | Biotech Hunter